Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)

Pharmaceutical Candidate Optimization (H.Sh., H.Su., T.L., M.Y., R.M.F., R.I., P.M., Y.L., A.D.R.), and Genomic Technologies (G.M.), Bristol-Myers Squibb Research and Development, Princeton, New Jersey; and Department of Bioanalytical Service, WuXi AppTec Co., Ltd., Shanghai, People’s Republic of China (L.L.)